Does EZETIMIBE Cause Second primary malignancy? 7 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with EZETIMIBE (Ezetimibe). This represents 0.1% of all adverse event reports for EZETIMIBE.
7
Reports of Second primary malignancy with EZETIMIBE
0.1%
of all EZETIMIBE reports
0
Deaths
7
Hospitalizations
How Dangerous Is Second primary malignancy From EZETIMIBE?
Of the 7 reports, 7 (100.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EZETIMIBE. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does EZETIMIBE Cause?
Myalgia (2,066)
Fatigue (876)
Drug ineffective (812)
Arthralgia (766)
Dyspnoea (766)
Nausea (742)
Dizziness (717)
Diarrhoea (688)
Headache (626)
Malaise (591)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which EZETIMIBE Alternatives Have Lower Second primary malignancy Risk?
EZETIMIBE vs EZETIMIBE\ROSUVASTATIN
EZETIMIBE vs EZETIMIBE\SIMVASTATIN
EZETIMIBE vs EZOGABINE
EZETIMIBE vs FACTOR XIII CONCENTRATE
EZETIMIBE vs FAM-TRASTUZUMAB DERUXTECAN-NXKI